Full-Time

Project Manager

Evidence Synthesis

Precision AQ

Precision AQ

501-1,000 employees

Data-driven drug access and launches

No salary listed

Remote in Canada

Remote

Remote within Canada.

Category
Business & Strategy (1)
Required Skills
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Precision AQ

See people who can refer or advise you

Requirements
  • 3+ years of experience in project management, preferably within consulting, life sciences, HEOR, market access, or related environments
  • Demonstrated experience managing complex, multi-disciplinary projects with multiple stakeholders
  • Experience working in a client-facing role, supporting or leading project management communications
  • Strong organizational, planning, and time-management skills, with the ability to manage multiple priorities simultaneously
  • Excellent written and verbal communication skills
  • Proficiency with Microsoft Office (Excel, PowerPoint, Word); familiarity with project tracking tools is an advantage
  • Ability to work effectively both independently and as part of a collaborative, cross-functional team
Responsibilities
  • Manage end-to-end project management across individual projects and portfolios of work, particularly Joint Clinical Assessment program
  • Plan, resourcing, timeline development, progress tracking, risk management, and delivery oversight across projects and portfolios of work
  • On client-facing projects, support or lead project management discussions, prepare and maintain project plans, timelines, and reports, and communicate status, risks, dependencies, and actions
  • Monitor scope changes and manage change order processes, clearly documenting impacts on timelines, resources, and budgets
  • Coordinate internal workflows, facilitate alignment across disciplines, document decisions and actions, and support monitoring and evaluation of agreed processes and milestones
  • Coordinate internal/external review cycle timelines and collate feedback from various external reviewers
  • Ensure on-time delivery, support financial and scope tracking, and escalate risks or resourcing issues early to project leadership
  • Work with clients to maintain an organized repository of deliverables
  • Support strategic portfolio oversight and prioritization, balancing competing demands, optimizing resource allocation, and aligning project execution with broader objectives
  • Develop and maintain standardized project management tools and templates, ensuring best practices across projects and teams; facilitate cross-project knowledge sharing and lessons learned
  • Leverage project management tools and data to generate insights for data-driven decision-making and transparent reporting for internal stakeholders and clients
  • Support proposal development and study start-up activities, including timeline development
Desired Qualifications
  • Experience supporting HEOR, evidence synthesis, health economics, modelling, or market access projects
  • Familiarity with Joint Clinical Assessment submissions, health technology assessment processes, or global evidence strategy programs
  • Experience coordinating work delivered by statisticians, health economists, and systematic review teams
  • Awareness of project financials, resourcing constraints, and scope management
  • A proactive, solutions-oriented mindset with strong problem-solving skills
  • High attention to detail and commitment to quality

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Precision AQ says it serves all 30 top pharma companies and launched 450-plus drugs.
  • April 25, 2025 oncology hires sharpen payer, provider, and formulary strategy for launches.
  • May 28, 2026 ASCO materials showcase OncoGenius and Navigator365 Matrix with 100-plus cancer centers.

What critics are saying

  • IQVIA, ICON, and Syneos Health crowd Precision AQ’s commercialization niche globally.
  • AI patient-services commoditization from Phluence-style tools compresses consulting margins by 2027.
  • Reliance on pharma launch budgets creates existential exposure if one major client insources access strategy.

What makes Precision AQ unique

  • Precision AQ’s AET has 25-plus former access decision-makers, built since 2009.
  • February 17, 2026 hires Emma Hawe and Yahya Anvar deepen HEOR, AI, and EU reach.
  • November 18, 2025 Phluence investment extends agentic post-Rx automation beyond traditional HUB models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...